AO-252
Ovarian Cancer, Endometrial Cancer, Triple-Negative Breast Cancer (TNBC)
Phase 1Dose Escalation & Expansion Planned
Key Facts
Indication
Ovarian Cancer, Endometrial Cancer, Triple-Negative Breast Cancer (TNBC)
Phase
Phase 1
Status
Dose Escalation & Expansion Planned
Company
About A2A Pharma
A2A Pharmaceuticals is a private, AI-driven drug discovery company focused on developing first-in-class therapeutics for life-threatening diseases, with a core emphasis on oncology. The company has achieved key milestones, including advancing its lead TACC3 inhibitor (AO-252) into Phase 1 clinical trials with early signs of efficacy and forming strategic partnerships with Biomea Fusion and Johnson & Johnson. Utilizing its SCULPT™ platform, A2A systematically designs novel chemical libraries to drug challenging targets, building a pipeline that includes inhibitors of MLL-Menin, TYK2 pseudokinase, YAP-TEAD, and a KRAS degrader.
View full company profile